In 1990 study in San Diego, CA the 5 active product and for subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had menopause flat or increased IgE levels.4 In a randomized, double-blind, placebo product controlled study of symptoms and serum IgE levels in San Diego, for CA in mid-1991, menopause subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. Seven of product the for 10 active treated subjects had a reduction in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total menopause serum IgE that stayed the same (plus or minus 5%), 3 decreased and 2 increased.5 product Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin B12 in lowering for serum IgE concentrations.

A new HAY FEVER breakthrough menopause clinically proven to reduce allergy product symptoms and antihistamine use. How long were symptoms reduced? Studies showed a one-year reduction. How long? for Yes, one year! this medication is a lozenge taken twice daily for 21 days. this medication is non-drowsy, natural and available without a prescription. menopause this medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing product the treatment without taking additional this medication. How long? Yes one year, compared for to 24-hour antihistamines it''s much longer lasting. Patients known to have seasonal allergy were examined in clinical studies in five U.S. states by qualified medical doctors. Each patient was given either the real this medication or a placebo (a dummy treatment). Nobody knew who got what. Patients recorded in symptons diaries how bad their symptoms were during and after the treatment. About one year later, patients completed a second diary. 64% of the group of patients menopause receiving this medication recorded less sneezing, product runny nose and nasal congestion for one year after completing menopause the treatment in a clinical study. This compares to 35% of the placebo group.